Edasalonexent Slows DMD Progression in Phase 2 Trial

Treatment with the Catabasis Pharmaceuticals small molecule oral NF-kB inhibitor resulted in improvements in the 10-meter walk/run scores, time-to-stand scores, and 4-stair climb scores in 31 steroid-naïve boys with DMD aged 4 to 7 years.

from Front page feed https://ift.tt/2BlgQm4